The European Commission (EC) has granted Orphan Drug Designation to L19TNF

Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.

PHILOGEN S.P.A. RECEIVES ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF SOFT-TISSUE SARCOMA